An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 63-72

  Pesa, Jacqueline A ^a   Van Den Bos, Jill ^b   Gray, Travis ^b   Hartsig, Colleen ^b   Mcqueen, Robert Brett ^c   Saseen, Joseph J ^c   Nair, Kavita V ^c  

^a Janssen Scientific Affairs LLC   (United States)

^b MILLIMAN INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Adherence; Cost sharing; Hypertension; Outcomes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GENERIC DRUG;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; SEX DIFFERENCE; TREND STUDY;

EID: 84857090408     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S28396     Document Type: Article

References (36)

1. Yoon SS, Ostchega Y, Louis T; Centers for Disease Control and Prevention. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. NCHS Data Brief No. 48; Oct 2010. Available at: http://www.cdc.gov/nchs/data/databriefs/db48.pdf. Accessed December 21, 2011.
2. Centers for Disease Control and Prevention. Diseases and Conditions. Available at: http://www.cdc.gov/DiseasesConditions/. Accessed August 26, 2011.
3. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003-1010.
4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics - 2010 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121(7):948-954.
5. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
6. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and Councils in Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
7. Copley JB, Rosario R. Hypertension: a review and rationale of treatment. Dis Mon. 2005;51(10-11):548-614.
8. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Collaboration. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004804/. Accessed January 9, 2012.
9. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-1196.
10. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentivebased formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
11. Yoon J, Ettner SL. Cost sharing and adherence to antihypertensives for low and high adherers. Am J Manag Care. 2009;15(11):833-840.
12. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-112.
13. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-e34.
14. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109-117.
15. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-2008.
16. Curtiss FR. Hypertension, prescription drug copayments, and drug therapy adherence. J Manag Care Pharm. 2003;9(5):454-456.
17. Milliman, Inc, Health Cost Guidelines. Available at: http://www.milliman.com/expertise/healthcare/products-tools/health-cost-guidelines/. Accessed December 21, 2011.
18. Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid lowering medication adherence in veterans. Circulation. 2009;119(3):390-397.
19. Houy M. Value-based benefit design: a purchaser guide [Internet]. Washington (DC): National Business Coalition on Health; 2009 Jan [cited August 26, 2010]. Value-based Benefit Design: a purchaser guide. Available at: http://www.sph.umich.edu/vbidcenter/publications/pdfs/VBBDPurchaserGuide%5B1%5D.pdf. Accessed December 21, 2011.
20. Nichol MB, Knight TK, Priest JL, et al. Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Mediaid population. J Am Pharm Assoc. 2010;50(4): 496-507.
21. Elliott WJ. Optimizing medication adherence in older persons with hypertension. Urol Nephrol. 2003;35(4):557-562.
22. Wogen J, Krellick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9(5):424-429.
23. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-2805.
24. DiMatteo MRP. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-209.
25. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54(Suppl 1):S57-S60.
26. Ellis S, Shumaker S, Sieber W, Rand C. Adherence to pharmacological interventions: current trends and future directions: the Pharmacological Intervention Working Group. Control Clin Trials. 2000;21(Suppl 5): S218-S225.
27. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134(10):1004-1006.
28. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21(5 Suppl):S188-S194.
29. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50(5): 619-625.
30. Johnson RE, Volmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc. 1991;39(11):1079-1084.
31. Steiner JF, Prochazka AV. The assessment of ref ill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.
32. Kirking DM, Ammann MA, Harrington C. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmacoepidemiol. 1996;5(1):3-15.
33. Fairman K, Motheral B. Evaluating medication adherence: Which measure is right for your program? J Manag Care Pharm. 2000;6(6): 499-502.
34. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9(2):123-133.
35. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing. JAMA. 2007;298(1):61-69.
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383.